Navigation Links
NW Bio's Patent Portfolio Further Expanded With Manufacturing Automation Patent
Date:9/10/2013

BETHESDA, Md., Sept. 10, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has been issued another key U.S. patent (#8,518,636) covering a next generation process for manufacturing lower cost human dendritic cells of both a higher quality and higher reliability.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

This next generation system has already been cleared by FDA for use in the manufacturing for NW Bio's clinical trials.  These systems are now in use producing the vaccines which already have been injected into the tumors of DCVax-Direct patients.

This next generation process automates certain crucial stages of the manufacturing process within a self-contained system.  Automating some or all of the production process within such a system can eliminate the need for today's extremely expensive "GMP" clean rooms (with, for example, special air handling to maintain sterile air in an entire building).  Eliminating the special costs for such clean rooms will further enhance product economics, allowing wider margins and pricing flexibility. 

At the heart of this next generation manufacturing advance are Tangential Flow Filtration machines, or TFF for short.  These machines and associated disposable sets provide an automated, closed system for the crucial stages of the manufacturing process isolating the particular immune cells that become the dendritic cells in the Company's DCVax products.

Most significantly, the dendritic cells produced through this next generation system, are manufactured using procedures which are more closely related to what one finds in nature.  The result is increased potency of the dendritic cells (which are the active agent in the DCVax products).

As such, full implementation of the TFF can be another major step forward in advancing immune therapies, and help to position the manufacturing of DCVax products for potential commercial scale-up when the time comes.

"Ongoing development of our technologies for cost reduction and simultaneous enhancements in quality continues to strengthen our competitive position," commented Linda Powers, CEO of NW Bio. "The TFF system provides major advantages in this regard, and the issuance of this latest patent is a significant addition to our portfolio of over 180 issued and pending patents worldwide."

Dr. Marnix Bosch, one of the inventors on this line of patents, says: "We have approached the issues of dendritic cell manufacturing from a process-improvement perspective, and the material covered in these issued patents takes advantage of the natural biology of dendritic cells and their precursors, thereby allowing us to produce more potent dendritic cells in a more efficient and automated system."

NW Bio holds numerous related international patents in Australia, Japan, New Zealand, Russia, China, South Korea, Mexico and other countries.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the U.S. and Europe.  The Company has a broad platform technology for DCVax dendritic cell-based vaccines.  The Company's lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. 

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements.  Actual results may differ materially from those projected in any forward-looking statement.  Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy.  Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings.  Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement.  You should not place undue reliance on any forward-looking statements.  The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Paragon Bioservices Wins CMO Leadership Awards for Third Consecutive Year
2. Rancho BioSciences Partners with OmicSoft for Manual Data Curation
3. Regado Biosciences, Inc. Announces Exercise of Over-Allotment Option
4. Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching Commercialization
5. Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
6. Rancho BioSciences Launches Rancho tranSMART Hosted for Clinical and Genomic Data Storage and Analysis
7. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
8. Indigo BioSystems, Inc. Ranks in the 2013 Inc. 500
9. 5000 for America's Fastest Growing Companies
10. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
11. Physician Familiarity With Biosimilars Has Increased Significantly Over The Past Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Fluxion Biosciences announced today that Genetracer Biotech of ... as a Certified Service Provider for Fluxion,s IsoFlux CTC ... in Genetracer Biotech,s novel liquid biopsy workflows for detection ... plans to move to other cancers as additional assays ... to isolate, recover, and analyze CTCs (circulating tumor cells) ...
(Date:2/27/2017)... ... , ... The Catalyst Midwest premix manufacturing facility has been certified ... and private label organic services. , The first organic product is Organic 18 Percent ... of Dynamite Marketing, which owns the facility. , Catalyst already has received the ...
(Date:2/25/2017)... ... February 25, 2017 , ... ... Trials in an ongoing effort to create meaningful change by increasing communication, ... research with emphasis on consumers and patients’ mental health well-being. , Both organizations ...
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
Breaking Biology Technology:
(Date:2/27/2017)... Feb. 27, 2017   Strategic Cyber Ventures , ... has led a $3.5 million investment in  Polarity , ... Cyber Ventures is DC based and is led by ... Thomas . Ron Gula , also a longtime ... participated in this series A round of funding. This ...
(Date:2/24/2017)... Feb. 24, 2017  EyeLock LLC, a leader of iris-based ... iris biometric solution on the latest Qualcomm® Snapdragon™ ... Mobile World Congress 2017 (February 27 – ... Hall 3, Stand 3E10. The ... security platform—a combination of hardware, software and ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
Breaking Biology News(10 mins):